Related Experiment Video
Updated: Oct 21, 2025
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small
Xue Zhou1,2, Ning Wang3, Yuefeng Zhang2
1Haihe Clinical College of Tianjin Medical University, Tianjin, 300350, China.
Background:
Over the past few years, dramatic breakthroughs in the field of tumor immunotherapy with immune checkpoint inhibitors (ICIs) have made a therapeutic revolution for non-small cell lung cancer (NSCLC). While only some patients present a favorable response to this treatment. It is urgent to explore the potential molecular mechanisms underlying the regulation of tumor immune microenvironment in the process of immunotherapy. Lysine acetyltransferase 2B (KAT2B) plays a crucial role in the regulation of gene expression at the post-transcriptional level by acetylation, and is associated with many types of cancer.
Methods:
RNA-sequencing data, genetic mutation data, and corresponding clinical information were extracted from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, then subjected to immune characteristics, gene expression, survival, genetic alteration, enrichment analyses.
Results:
KAT2B expression correlated positively with infiltrating levels of multiple immune cells and mRNA expression levels of immune checkpoint genes in NSCLC. Furthermore, KAT2B expression was downregulated in tumor tissues, and low KAT2B expression was associated with unsatisfactory efficacy of immune checkpoint blockade (ICB) and poor prognosis of patients with lung adenocarcinoma. Moreover, there were higher somatic genes mutation frequency in patients with low expression of KAT2B. Finally, functional enrichment analysis suggested that KAT2B was mainly linked to the regulation of immune cells and interferon - gamma (IFN-γ) mediated signaling pathways, response to IFN-γ, antigen processing and presentation.
Conclusion:
This is the first comprehensive study to disclose that KAT2B is correlated with immune infiltrates and may serve as a novel biomarker predicting prognosis and response to immunotherapy in NSCLC.
Insights
Lysine acetyltransferase 2B (KAT2B) is linked to immune cell infiltration in non-small cell lung cancer (NSCLC). Low KAT2B expression predicts poor response to immunotherapy and survival in NSCLC patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancer (NSCLC) treatment.
- However, predicting patient response to ICIs remains a challenge.
- Understanding the tumor immune microenvironment is crucial for improving immunotherapy efficacy.
Purpose of the Study:
- To investigate the role of Lysine acetyltransferase 2B (KAT2B) in NSCLC immunity.
- To explore KAT2B as a potential biomarker for immunotherapy response and patient prognosis.
Main Methods:
- Utilized RNA-sequencing and mutation data from TCGA and GEO databases.
- Analyzed immune cell infiltration, gene expression, survival, and genetic alterations.
- Performed functional enrichment analyses to understand KAT2B's biological pathways.
Main Results:
- KAT2B expression positively correlated with immune cell infiltration and immune checkpoint gene expression in NSCLC.
- Downregulated KAT2B in tumor tissues was associated with poor response to immune checkpoint blockade (ICB) and worse prognosis.
- Low KAT2B expression correlated with higher somatic mutation frequency and linked to immune cell regulation and IFN-γ signaling pathways.
Conclusions:
- KAT2B is significantly correlated with immune infiltrates in NSCLC.
- KAT2B may serve as a novel predictive biomarker for prognosis and immunotherapy response in NSCLC patients.
Related Concept Videos
01:27Tumor Immunotherapy
02:39lncRNA - Long Non-coding RNAs